Publications by authors named "Yazan Alsayed"

Claim this Profile
E
Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.
Alissa Huston, Xavier Leleu, Xiaoying Jia, Anne-Sophie Moreau, Hai T Ngo, Yazan Alsayed

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Saad Z Usmani, Christoph Heuck, Alan Mitchell, Jackie Szymonifka, Bijay Nair, Yazan Alsayed

Haematologica· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Christoph J Heuck, Jackie Szymonifka, Emily Hansen, John D Shaughnessy, Saad Z Usmani, Yazan Alsayed

Clin Cancer Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
John D Shaughnessy, Pingping Qu, Saad Usmani, Christoph J Heuck, Qing Zhang, Yazan Alsayed

Blood· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Sarah Waheed, John D Shaughnessy, Frits van Rhee, Yazan Alsayed, Bijay Nair

Cancer· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Frits van Rhee, Jackie Szymonifka, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed

Blood· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Bijay Nair, Frits van Rhee, John D Shaughnessy, Elias Anaissie, Jackie Szymonifka, Yazan Alsayed

Blood· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
Yiming Zhou, Lijuan Chen, Bart Barlogie, Owen Stephens, Xiaosong Wu, Yazan Alsayed

Proc Natl Acad Sci U S A· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
John D Shaughnessy, Yiming Zhou, Jeff Haessler, Frits van Rhee, Elias Anaissie, Yazan Alsayed

Br J Haematol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Antje Hoering, John Crowley, John D Shaughnessy, Klaus Hollmig, Yazan Alsayed

Blood· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Bijay Nair, John D Shaughnessy, Yiming Zhou, Marie Astrid-Cartron, Pingping Qu, Yazan Alsayed

Blood· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Yazan Alsayed

Blood· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomics analysis in post-transplant lymphoproliferative disorders.
Yazan Alsayed, Xavier Leleu, Alexey Leontovich, Ana B Oton, Mona Melhem

Eur J Haematol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Bart Barlogie, Frits van Rhee, John D Shaughnessy, Joshua Epstein, Shmuel Yaccoby, Yazan Alsayed

Blood· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
Bart Barlogie, Elias Anaissie, Jeffrey Haessler, Fritz van Rhee, Mauricio Pineda-Roman, Yazan Alsayed

Cancer· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Alissa Huston, Xavier Leleu, Xiaoying Jia, Anne-Sophie Moreau, Hai T Ngo, Yazan Alsayed

Clin Cancer Res· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Bart Barlogie, Guido Tricot, Jeff Haessler, Frits van Rhee, Michele Cottler-Fox, Yazan Alsayed

Blood· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Jeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, John Crowley, Joshua Epstein, Yazan Alsayed

Clin Cancer Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda-Roman, Elias Anaissie, Yazan Alsayed

Blood· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Bart Barlogie, Elias Anaissie, Frits van Rhee, Jeffrey Haessler, Klaus Hollmig, Yazan Alsayed

Br J Haematol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Anne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, Xavier Leleu, Garrett O'Sullivan, Yazan Alsayed

Blood· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
John D Shaughnessy, Jeffrey Haessler, Frits van Rhee, Elias Anaissie, Mauricio Pineda-Roman, Yazan Alsayed

Br J Haematol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Yazan Alsayed, Hai Ngo, Judith Runnels, Xavier Leleu, Ujjal K Singha

Blood· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic analysis of waldenstrom macroglobulinemia.
Evdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, Xavier Leleu, Michael Timm, Yazan Alsayed

Cancer Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Lanie K Francis, Yazan Alsayed, Xavier Leleu, Xiaoying Jia, Ujjal K Singha

Clin Cancer Res· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis